---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-045309"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T10:16:03.650841+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Positive topline results from VIRAGE Phase 2b trial: VCN-01+SoC improves OS, PFS, DoR in metastatic pancreatic cancer

## Summary
- Median OS 10.8 vs 8.6 months for VCN-01+SoC vs SoC alone (HR=0.57, p=0.0546).
- Median PFS 7.0 vs 4.6 months (HR=0.55, p=0.0105).
- Median DoR doubled to 11.2 vs 5.4 months (HR=0.22, p=0.0035).
- 2-dose VCN-01 + ≥4 cycles SoC subgroup: median OS 14.8 vs 11.6 months (HR=0.44, p=0.046).
- Safety met primary endpoint; AEs transient/reversible, consistent with prior trials.

## SEC filing metadata
- accession: 0001104659-25-045309
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/0001104659-25-045309-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925045309/tm2514050d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-045309
- JSON: https://secwatch.observer/filing/0001104659-25-045309.json
- Plain text: https://secwatch.observer/filing/0001104659-25-045309.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.